Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of XTYW007 in Healthy Subjects and Subjects With Elevated LDL-C
NCT07407634Phase 1Not yet recruiting
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XTYW007 in non-alcoholic fatty liver disease (NAFLD) and hypercholesterolemia (3 arms), sponsored by Xi'an Xintong Pharmaceutical Research Co., Ltd. Primary endpoints: Treatment-related adverse events, Maximum Observed Plasma Concentration and 6 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
XTYW007
03
Conditions
non-alcoholic fatty liver disease (NAFLD)hypercholesterolemia
Beyond the preview
Go deeper on NCT07407634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407634.